Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for Trappsol® Cyclo™ in Niemann-Pick Disease Type C - read this article along with other careers information, tips and advice on BioSpace
Anteris Technologies Ltd partners with medtech heavyweights for FDA early feasibility study proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Argonne s Advanced Photon Source guided the development of new COVID-19 vaccine now in trials
Human clinical trials have begun on a new vaccine candidate that may protect against not only SARS-CoV-2, the virus that causes COVID-19, but against at least two of the variants emerging around the world. The development of this new vaccine was guided by structural information on the virus obtained at the Advanced Photon Source (APS), a U.S. Department of Energy (DOE) Office of Science User Facility at DOE s Argonne National Laboratory, and other light sources.
Trials are taking place at the Walter Reed Army Institute of Research (WRAIR), part of the U.S. Army Medical Research and Development Command, following up on early tests that showed promising results.
Argonne s Advanced Photon Source plays pivotal role in new COVID-19 vaccine now in trials eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Army Begins Clinical Trials on Vaccine That May Be Effective Against All Coronaviruses
Officer receives the Pfizer-BioNTech COVID-19 vaccine at the Conroy Bowl on Schofield Barracks, Hawaii on Jan. 14, 2021. (U.S. Army/1st Lt. Angelo Mejia)
6 Apr 2021
Fifteen months after launching an effort to develop a vaccine against COVID-19, the Walter Reed Army Institute of Research is preparing for a clinical trial, seeking volunteers for a small safety study.
The Army s vaccine candidate uses a new technology involving a Spike Ferritin Nanoparticle, or SpFN, that researchers hope can be adapted to protect against any coronavirus, including those that cause the common cold or deadly diseases such as COVID-19, Severe Acute Respiratory Syndrome, or SARS, and Middle East Respiratory Syndrome, MERS.